Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

By | December 27, 2022
Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT).